From clinical validation to commercialisation: Stablepharma enters a pivotal new chapter
We’ve stopped talking about what our technology could do and started showing it in people.
The Phase 1 results were a huge moment for us. SPVX02 had a strong safety profile and immune responses comparable to the licensed refrigerated vaccine. Having that peer-reviewed in a Lancet journal is about as strong a validation of the StablevaX™ science as you can get.
So we’re moving from proof of concept towards commercialisation, and that’s a very exciting place to be.
Q: Why does SPVX02 matter beyond being one vaccine?
Because it proves a much bigger idea. SPVX02 is a reformulation of an existing vaccine. We’ve shown we can take it out of the fridge without losing what makes it work.
And that’s our whole business: taking temperature-sensitive vaccines and medicines and reformulating them so they can be stored, shipped and stockpiled without the need for a cold chain. SPVX02 is our lead product, but it’s also the clinical proof point for the entire platform.
Q: The Phase 2b trial is now under way. How important is it?
It’s a pivotal trial. We’re enrolling 160 healthy adults to show that SPVX02’s immune response is non-inferior to the licensed comparator.
What’s really exciting is what it means for the future. For reformulations like this, the pathway can be relatively lean. That has big implications for cost and timelines every time we apply the platform to a new product, especially with the right partners alongside us.
When I think back to the early StablevaX™ work, it’s quite something to be at the stage of testing, in a pivotal trial, whether a vaccine can be freed from the fridge.
Q: You’ve signed a major partnership with AFT Pharmaceuticals. What does that say about where Stablepharma is heading?
It shows the opportunity goes well beyond vaccines.
In January we signed a development and option-to-license agreement with AFT covering up to 14 pharmaceutical products, starting with areas like anti-infectives and oncology, in markets worth more than US$6 billion combined. The first programmes are already running. Then in June we signed a Letter of Intent with AFT for the proposed distribution of SPVX02 in the UK, Canada, Australia and New Zealand, with an option to extend into Singapore and Hong Kong.
That’s the model. We don’t need to build an integrated pharma company that does everything itself. Our expertise is making medicines thermostable. Partners like AFT bring the products, investment, market knowledge and routes to patients. Together it’s a much faster, more efficient way to get these innovations out there.
So, the vision hasn’t changed, but the scale of it has. I now think of Stablepharma as a thermostabilisation partner to the pharmaceutical industry, not just a vaccine company.
Q: SPVX02 was named one of TIME’s Best Inventions of 2026. What did that mean to you?
It was an extraordinary moment for the whole team.
When you’re taking on something as embedded as the pharmaceutical cold chain, there are times when you have to keep believing in the science before everyone else can see it. It is like telling people that it is now possible to have an ice cream on the beach without a freezer to store it. Recognition like this puts the technology in front of a completely new audience.
But for me, what matters is what was recognised: a simple ambition to make essential medicines easier to store, move and, ultimately, access.
Q: Why does getting medicines out of the fridge matter so much?
The obvious answer is access, in places where electricity and a reliable cold chain can’t be taken for granted.
But it matters in well-resourced health systems too: simpler logistics, less wastage, more flexibility. And there’s an environmental angle, because refrigeration burns energy at every step of the supply chain.
So, this isn’t just a solution for low-income countries. It can make healthcare supply chains simpler, more resilient and more sustainable everywhere.
Q: You’re raising a Series B. What will it allow you to do?
It’s about turning a clinically validated platform into a scalable, partner-led commercial business. The raise will extend our runway, progress SPVX02 towards commercialisation and, crucially, strengthen our R&D and business development teams.
Our model only scales if we can develop more products in parallel and keep bringing great partners into the pipeline. That’s where this investment goes.
Q: What do the next 12 to 24 months look like?
Really, there are two engines running side by side.
The first is SPVX02: delivering the Phase 2b trial and moving towards marketing authorisation and commercialisation.
The second is the platform. Beyond AFT, we’re in active conversations with vaccine manufacturers, generics companies, governments and pharma partners, and our aim is to add at least one new revenue-generating partnership a year.
Q: You’ve been a BIA member through a period of real growth. What role does the UK ecosystem play?
A huge one. Our clinical development has happened here, we work closely within the UK regulatory and life sciences community, and the Phase 2b trial is running here. We have partnered with UKRI, UKHSA, NIHR amongst others.
The UK has world-class science, clinical, regulatory and investment expertise. The challenge now is making sure great UK innovations don’t just get started here, but scale into global businesses. The connections BIA gives us become even more valuable as we head towards commercialisation.
Q: Last time, you said Stablepharma was entering a “new era” in vaccines. Do you still believe that?
More than ever, although I’d broaden it now.
What started as fridge-free vaccines has become a chance to rethink how a whole range of temperature-sensitive medicines are made, stored and distributed. We have human clinical data, a pivotal trial under way, an international commercial partner and growing global recognition.
So, the question has changed from “Can we do this?” to “How far can we take it?” And that’s a much more exciting question to answer.
This is a guest blog. Its author/s is/are responsible for content within it, which does not necessarily reflect the opinions or positions of BIA.